{"id":1328,"date":"2022-08-26T14:25:33","date_gmt":"2022-08-26T14:25:33","guid":{"rendered":"https:\/\/www.vdh.virginia.gov\/clinicians\/?page_id=1328"},"modified":"2022-08-26T14:25:33","modified_gmt":"2022-08-26T14:25:33","slug":"covid-19-and-monkeypox-updates-for-virginia","status":"publish","type":"page","link":"https:\/\/www.vdh.virginia.gov\/clinicians\/covid-19-and-monkeypox-updates-for-virginia\/","title":{"rendered":"COVID-19 and Monkeypox Updates for Virginia"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-1137\" src=\"https:\/\/www.vdh.virginia.gov\/content\/uploads\/sites\/134\/2022\/04\/Letterhead-Greene_2022-1.png\" alt=\"\" width=\"1700\" height=\"452\" \/><\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: center\"><b>COVID-19 and Monkeypox Updates for Virginia<\/b><\/p>\n<p style=\"text-align: center\"><span style=\"font-weight: 400\">August 26, 2022<\/span><\/p>\n<p><span style=\"font-weight: 400\">Dear Colleague:<\/span><\/p>\n<p><span style=\"font-weight: 400\">I am writing to provide you brief updates on COVID-19 and monkeypox.<\/span><\/p>\n<p><b>CDC Updates COVID-19 Recommendations<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">On August 11, the Centers for Disease Control and Prevention (CDC) made substantial <\/span><a href=\"https:\/\/www.cdc.gov\/mmwr\/volumes\/71\/wr\/mm7133e1.htm\"><span style=\"font-weight: 400\">COVID-19 guidance<\/span><\/a><span style=\"font-weight: 400\"> updates and recommends that in light of high population levels of anti\u2013SARS-CoV-2 seroprevalence, and to limit social and economic impacts, quarantine of exposed persons is no longer recommended, regardless of vaccination status.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">CDC recommends that people who have had recent confirmed or suspected exposure to an infected person should wear a mask for 10 days around others when indoors in public and should receive testing \u2265 5 days after exposure (or sooner, if they are symptomatic), irrespective of their vaccination status.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">CDC recommends case investigation and contact tracing only in health care settings and certain high-risk congregate settings. In all other circumstances, public health efforts can focus on case notification and provision of information and resources to exposed persons about access to testing.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Everyone is encouraged to stay up-to-date on their COVID-19 vaccinations and use the <\/span><a href=\"https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/your-health\/covid-by-county.html\"><span style=\"font-weight: 400\">COVID-19 Community Levels<\/span> <\/a><span style=\"font-weight: 400\">to guide additional prevention efforts for themselves, based on their own personal risk.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">CDC continues to recommend masking at all times in healthcare settings, regardless of the current COVID-19 Community Level.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">The elimination of most quarantine for COVID is in concurrence with VDH policy.\u00a0 VDH policy leaves masking as a personal choice in most circumstances; exceptions are high-risk settings including healthcare delivery, and as part of an isolation protocol, where masking is still recommended.<\/span><\/li>\n<\/ul>\n<p><b>COVID-19 Vaccine Update: Novavax and Bivalent Boosters\u00a0<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">FDA recently <\/span><a href=\"https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/novavax-covid-19-vaccine-adjuvanted\"><span style=\"font-weight: 400\">authorized<\/span><\/a><span style=\"font-weight: 400\"> and CDC <\/span><a href=\"https:\/\/www.cdc.gov\/media\/releases\/2022\/s0822-novax-vaccine.html\"><span style=\"font-weight: 400\">recommended<\/span><\/a><span style=\"font-weight: 400\"> Novavax\u2019s COVID-19 vaccine as another primary series option for adolescents aged 12 through 17 years.\u00a0 Previously, this vaccine had been recommended for adults aged 18 years and older.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">To reflect the expanded age eligibility, FDA updated their <\/span><a href=\"https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/novavax-covid-19-vaccine-adjuvanted\"><span style=\"font-weight: 400\">fact sheets<\/span><\/a><span style=\"font-weight: 400\"> for healthcare providers and for patients and caregivers, and CDC updated its <\/span><a href=\"https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/covid-19-vaccines-us.html\"><span style=\"font-weight: 400\">Interim Clinical Considerations for the Use of COVID-19 Vaccines in the United States<\/span><\/a><span style=\"font-weight: 400\">.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Providers in Virginia may immediately begin using this 2-dose primary series vaccine for these adolescents.\u00a0 As a reminder, Novavax\u2019s COVID-19 vaccine cannot be used for a booster dose or for third doses for immunocompromised persons.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">In the near future, FDA and CDC might provide information about new bivalent COVID-19 vaccine boosters that cover an Omicron BA.4\/5 spike protein, and that might be available in the 2022 fall and winter.\u00a0<\/span><\/li>\n<\/ul>\n<p><b>COVID-19 Therapeutic Update: Bebtelovimab is Available for Purchase Commercially<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">As of August 15, 2022, bebtelovimab has become <\/span><a href=\"https:\/\/aspr.hhs.gov\/COVID-19\/Therapeutics\/updates\/Pages\/important-update-11August2022.aspx#:~:text=The%20US%20Food%20and%20Drug,commercial%20distribution%20of%20the%20product.\"><span style=\"font-weight: 400\">commercially available for purchase<\/span><span style=\"font-weight: 400\">.<\/span><\/a><span style=\"font-weight: 400\"> Orders can be placed directly through AmerisourceBergen.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">The federal government will allocate its remaining supply of bebtelovimab to jurisdictions. Providers should not bill patients or insurance for any product procured from the federal government.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">VDH places a high priority on equitable availability of bebtelovimab. If a facility does not serve the under and\/or uninsured, VDH encourages these locations to utilize the <\/span><a href=\"https:\/\/redcap.vdh.virginia.gov\/redcap\/surveys\/?s=XT4WFMD979\"><span style=\"font-weight: 400\">redistribution process<\/span><\/a><span style=\"font-weight: 400\"> to reallocate bebtelovimab procured from the federal government for this vulnerable population.\u00a0<\/span><\/li>\n<\/ul>\n<p><b>Monkeypox Clinical Evaluation and Management<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">CDC recently published a <\/span><a href=\"https:\/\/www.cdc.gov\/mmwr\/volumes\/71\/wr\/mm7132e3.htm?s_cid=mm7132e3_w\"><span style=\"font-weight: 400\">report<\/span><\/a><span style=\"font-weight: 400\"> describing the clinical and epidemiologic features of U.S. monkeypox cases.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Coinfections with sexually transmitted infections (STIs), like HIV, have been reported. To date, there have been no reported U.S.deaths.\u00a0 Lesions, however, can be painful or pruritic as they progress.\u00a0 Some patients require hospitalization.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">As a reminder, all healthcare staff should implement <\/span><a href=\"https:\/\/www.cdc.gov\/poxvirus\/monkeypox\/clinicians\/infection-control.html\"><span style=\"font-weight: 400\">standard and transmission-based precautions<\/span><\/a><span style=\"font-weight: 400\"> when providing care to a patient with suspected or confirmed monkeypox. VDH has received reports of healthcare staff not using appropriate PPE when performing initial triage or collecting vital information, which puts those individuals at risk.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">For patients with monkeypox, supportive care should be assessed and provided for management of pain, skin and oral lesions, proctitis, and gastrointestinal symptoms.\u00a0 This treatment might include over-the-counter or prescription medication for acute pain management, baths or topical gels for painful or itchy lesions, oral histamines for pruritus, an<\/span><span style=\"font-weight: 400\">d rehydration for fluid losses<\/span><span style=\"font-weight: 400\">.\u00a0 Providers can refer to <\/span><a href=\"https:\/\/www1.nyc.gov\/assets\/doh\/downloads\/pdf\/cd\/monkeypox-treatment-guidance-interim.pdf\"><span style=\"font-weight: 400\">New York City Department of Health &amp; Mental Hygiene\u2019s guidance on supportive care<\/span><\/a><span style=\"font-weight: 400\">.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Antiviral treatment using tecovirimat (TPOXX) is available through an <\/span><a href=\"https:\/\/www.cdc.gov\/poxvirus\/monkeypox\/pdf\/Tecovirimat-IND-Protocol-CDC-IRB.pdf\"><span style=\"font-weight: 400\">Expanded Access &#8211; Investigational New Drug<\/span><\/a><span style=\"font-weight: 400\"> (EA-IND) protocol authorized by the CDC for patients with severe illness or those at <\/span><a href=\"https:\/\/www.cdc.gov\/poxvirus\/monkeypox\/clinicians\/treatment.html\"><span style=\"font-weight: 400\">high risk<\/span><\/a><span style=\"font-weight: 400\"> of severe illness.\u00a0<\/span>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">It is provided by the federal government at no cost; patients should not be billed for the drug, but may be billed for the healthcare encounter.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">It may be prescribed after obtaining informed consent.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Virtual evaluations (telemedicine) are allowed.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Additional documentation requirements can be found on the <\/span><a href=\"https:\/\/www.cdc.gov\/poxvirus\/monkeypox\/clinicians\/obtaining-tecovirimat.html#:~:text=Protocol,monkeypox%2C%20in%20adults%20and%20children.\"><span style=\"font-weight: 400\">CDC Information for Healthcare Providers on Obtaining and Using TPOXX (Tecovirimat) for Treatment of Monkeypox<\/span><\/a><span style=\"font-weight: 400\"> website.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">To access TPOXX, providers should follow the steps on <\/span><a href=\"https:\/\/www.vdh.virginia.gov\/surveillance-and-investigation\/monkeypox\/information-for-healthcare-providers\/treatment-of-monkeypox\/\"><span style=\"font-weight: 400\">VDH\u2019s Monkeypox Treatment website for providers<\/span><\/a><span style=\"font-weight: 400\">.\u00a0<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><b>JYNNEOS Vaccine for People at High Risk of Exposure to the Monkeypox Virus<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">On August 9, FDA <\/span><a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/monkeypox-update-fda-authorizes-emergency-use-jynneos-vaccine-increase-vaccine-supply\"><span style=\"font-weight: 400\">issued<\/span><\/a> <span style=\"font-weight: 400\">an emergency use authorization (EUA) for the JYNNEOS vaccine, which will allow for an expanded U.S. supply.\u00a0 The <\/span><span style=\"font-weight: 400\">standard<\/span><span style=\"font-weight: 400\"> vaccine dosing regimen is to administer 0.5ml of the vaccine <\/span><span style=\"font-weight: 400\">subcutaneously<\/span><span style=\"font-weight: 400\">.\u00a0 Under the EUA, an <\/span><span style=\"font-weight: 400\">alternative<\/span><span style=\"font-weight: 400\"> regimen of 0.1ml administered <\/span><span style=\"font-weight: 400\">intradermally<\/span><span style=\"font-weight: 400\"> is available for people aged 18 years or older.\u00a0\u00a0<\/span>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Adults who received their first dose subcutaneously may receive their second dose intradermally or subcutaneously.<\/span><span style=\"font-weight: 400\">\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">The EUA also expanded vaccine eligibility to people younger than 18 years of age using the <\/span><span style=\"font-weight: 400\">standard<\/span><span style=\"font-weight: 400\"> vaccine dosing regimen.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">At this time all JYNNEOS vaccines are administered by local health departments and a small number of select community providers.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">If you are a provider caring for a person who is eligible for JYNNEOS, including children, please contact your local health department for information on how to access the vaccine for your patients.\u00a0<\/span><\/li>\n<\/ul>\n<\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Effective today (August 25), the following groups of people are now eligible to receive Expanded Postexposure Prophylaxis (PEP) in Virginia:<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">All people, of any sexual orientation or gender, who have had anonymous or multiple (more than 1) sexual partners in the last 2 weeks; or<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Sex workers (of any sexual orientation or gender); or<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Staff (of any sexual orientation or gender) at establishments where sexual activity occurs (e.g. bathhouses, saunas, sex clubs).<\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Please familiarize yourself with eligibility criteria for JYNNEOS vaccine in Virginia, and visit the <\/span><a href=\"https:\/\/www.vdh.virginia.gov\/surveillance-and-investigation\/monkeypox\/monkeypox-information-for-healthcare-professionals\/monkeypox-vaccine\/\"><span style=\"font-weight: 400\">VDH website<\/span><\/a><span style=\"font-weight: 400\"> regularly to obtain the most current information.\u00a0<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400\">Thank you again for your continued partnership.\u00a0 <\/span><span style=\"font-weight: 400\">Please visit the<\/span> <a href=\"https:\/\/www.vdh.virginia.gov\/\"><span style=\"font-weight: 400\">VDH websit<\/span><span style=\"font-weight: 400\">e<\/span><\/a> <span style=\"font-weight: 400\">for current clinical and public health guidance on <\/span><a href=\"https:\/\/www.vdh.virginia.gov\/coronavirus\/\"><span style=\"font-weight: 400\">COVID-19<\/span><\/a><span style=\"font-weight: 400\"> and <\/span><a href=\"https:\/\/www.vdh.virginia.gov\/surveillance-and-investigation\/monkeypox\/monkeypox-information-for-healthcare-professionals\/\"><span style=\"font-weight: 400\">monkeypox<\/span><\/a><span style=\"font-weight: 400\">. <\/span><b>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/b><\/p>\n<p><span style=\"font-weight: 400\">Sincerely,<\/span><\/p>\n<p><span style=\"font-weight: 400\">Colin M. Greene, MD, MPH<\/span><br \/>\n<span style=\"font-weight: 400\">State Health Commissioner\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 <\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; COVID-19 and Monkeypox Updates for Virginia August 26, 2022 Dear Colleague: I am writing to provide you brief updates on COVID-19 and monkeypox. CDC Updates COVID-19 Recommendations On August 11, the Centers for Disease Control and Prevention (CDC) made substantial COVID-19 guidance updates and recommends that in light of high population levels of anti\u2013SARS-CoV-2 [&hellip;]<\/p>\n","protected":false},"author":428,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"tags":[],"class_list":["post-1328","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>COVID-19 and Monkeypox Updates for Virginia - Clinicians<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.vdh.virginia.gov\/clinicians\/covid-19-and-monkeypox-updates-for-virginia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"COVID-19 and Monkeypox Updates for Virginia - Clinicians\" \/>\n<meta property=\"og:description\" content=\"&nbsp; COVID-19 and Monkeypox Updates for Virginia August 26, 2022 Dear Colleague: I am writing to provide you brief updates on COVID-19 and monkeypox. CDC Updates COVID-19 Recommendations On August 11, the Centers for Disease Control and Prevention (CDC) made substantial COVID-19 guidance updates and recommends that in light of high population levels of anti\u2013SARS-CoV-2 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.vdh.virginia.gov\/clinicians\/covid-19-and-monkeypox-updates-for-virginia\/\" \/>\n<meta property=\"og:site_name\" content=\"Clinicians\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.vdh.virginia.gov\/content\/uploads\/sites\/134\/2022\/04\/Letterhead-Greene_2022-1.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.vdh.virginia.gov\\\/clinicians\\\/covid-19-and-monkeypox-updates-for-virginia\\\/\",\"url\":\"https:\\\/\\\/www.vdh.virginia.gov\\\/clinicians\\\/covid-19-and-monkeypox-updates-for-virginia\\\/\",\"name\":\"COVID-19 and Monkeypox Updates for Virginia - Clinicians\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.vdh.virginia.gov\\\/clinicians\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.vdh.virginia.gov\\\/clinicians\\\/covid-19-and-monkeypox-updates-for-virginia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.vdh.virginia.gov\\\/clinicians\\\/covid-19-and-monkeypox-updates-for-virginia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.vdh.virginia.gov\\\/content\\\/uploads\\\/sites\\\/134\\\/2022\\\/04\\\/Letterhead-Greene_2022-1.png\",\"datePublished\":\"2022-08-26T14:25:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.vdh.virginia.gov\\\/clinicians\\\/covid-19-and-monkeypox-updates-for-virginia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.vdh.virginia.gov\\\/clinicians\\\/covid-19-and-monkeypox-updates-for-virginia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.vdh.virginia.gov\\\/clinicians\\\/covid-19-and-monkeypox-updates-for-virginia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.vdh.virginia.gov\\\/content\\\/uploads\\\/sites\\\/134\\\/2022\\\/04\\\/Letterhead-Greene_2022-1.png\",\"contentUrl\":\"https:\\\/\\\/www.vdh.virginia.gov\\\/content\\\/uploads\\\/sites\\\/134\\\/2022\\\/04\\\/Letterhead-Greene_2022-1.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.vdh.virginia.gov\\\/clinicians\\\/covid-19-and-monkeypox-updates-for-virginia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.vdh.virginia.gov\\\/clinicians\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"COVID-19 and Monkeypox Updates for Virginia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.vdh.virginia.gov\\\/clinicians\\\/#website\",\"url\":\"https:\\\/\\\/www.vdh.virginia.gov\\\/clinicians\\\/\",\"name\":\"Clinicians\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.vdh.virginia.gov\\\/clinicians\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"COVID-19 and Monkeypox Updates for Virginia - Clinicians","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.vdh.virginia.gov\/clinicians\/covid-19-and-monkeypox-updates-for-virginia\/","og_locale":"en_US","og_type":"article","og_title":"COVID-19 and Monkeypox Updates for Virginia - Clinicians","og_description":"&nbsp; COVID-19 and Monkeypox Updates for Virginia August 26, 2022 Dear Colleague: I am writing to provide you brief updates on COVID-19 and monkeypox. CDC Updates COVID-19 Recommendations On August 11, the Centers for Disease Control and Prevention (CDC) made substantial COVID-19 guidance updates and recommends that in light of high population levels of anti\u2013SARS-CoV-2 [&hellip;]","og_url":"https:\/\/www.vdh.virginia.gov\/clinicians\/covid-19-and-monkeypox-updates-for-virginia\/","og_site_name":"Clinicians","og_image":[{"url":"https:\/\/www.vdh.virginia.gov\/content\/uploads\/sites\/134\/2022\/04\/Letterhead-Greene_2022-1.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.vdh.virginia.gov\/clinicians\/covid-19-and-monkeypox-updates-for-virginia\/","url":"https:\/\/www.vdh.virginia.gov\/clinicians\/covid-19-and-monkeypox-updates-for-virginia\/","name":"COVID-19 and Monkeypox Updates for Virginia - Clinicians","isPartOf":{"@id":"https:\/\/www.vdh.virginia.gov\/clinicians\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.vdh.virginia.gov\/clinicians\/covid-19-and-monkeypox-updates-for-virginia\/#primaryimage"},"image":{"@id":"https:\/\/www.vdh.virginia.gov\/clinicians\/covid-19-and-monkeypox-updates-for-virginia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.vdh.virginia.gov\/content\/uploads\/sites\/134\/2022\/04\/Letterhead-Greene_2022-1.png","datePublished":"2022-08-26T14:25:33+00:00","breadcrumb":{"@id":"https:\/\/www.vdh.virginia.gov\/clinicians\/covid-19-and-monkeypox-updates-for-virginia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.vdh.virginia.gov\/clinicians\/covid-19-and-monkeypox-updates-for-virginia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.vdh.virginia.gov\/clinicians\/covid-19-and-monkeypox-updates-for-virginia\/#primaryimage","url":"https:\/\/www.vdh.virginia.gov\/content\/uploads\/sites\/134\/2022\/04\/Letterhead-Greene_2022-1.png","contentUrl":"https:\/\/www.vdh.virginia.gov\/content\/uploads\/sites\/134\/2022\/04\/Letterhead-Greene_2022-1.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.vdh.virginia.gov\/clinicians\/covid-19-and-monkeypox-updates-for-virginia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.vdh.virginia.gov\/clinicians\/"},{"@type":"ListItem","position":2,"name":"COVID-19 and Monkeypox Updates for Virginia"}]},{"@type":"WebSite","@id":"https:\/\/www.vdh.virginia.gov\/clinicians\/#website","url":"https:\/\/www.vdh.virginia.gov\/clinicians\/","name":"Clinicians","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.vdh.virginia.gov\/clinicians\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.vdh.virginia.gov\/clinicians\/wp-json\/wp\/v2\/pages\/1328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.vdh.virginia.gov\/clinicians\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.vdh.virginia.gov\/clinicians\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.vdh.virginia.gov\/clinicians\/wp-json\/wp\/v2\/users\/428"}],"replies":[{"embeddable":true,"href":"https:\/\/www.vdh.virginia.gov\/clinicians\/wp-json\/wp\/v2\/comments?post=1328"}],"version-history":[{"count":1,"href":"https:\/\/www.vdh.virginia.gov\/clinicians\/wp-json\/wp\/v2\/pages\/1328\/revisions"}],"predecessor-version":[{"id":1330,"href":"https:\/\/www.vdh.virginia.gov\/clinicians\/wp-json\/wp\/v2\/pages\/1328\/revisions\/1330"}],"wp:attachment":[{"href":"https:\/\/www.vdh.virginia.gov\/clinicians\/wp-json\/wp\/v2\/media?parent=1328"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.vdh.virginia.gov\/clinicians\/wp-json\/wp\/v2\/tags?post=1328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}